Chimerix Investor Conference Presentation Deck
Summary
ONC201 monotherapy exhibited durable and clinically meaningful efficacy in recurrent H3 K27M-mutant
DMG patients
-
RANO-HGG criteria assessed by dual reader BICR
ORR 20% (95% CI: 10-34%)
32
●
●
●
RANO-LGG criteria assessed by dual reader BICR
ORR 26% (95% CI: 15-40%)
Median DOR 11.2 months (95% CI: 3.8 - not reached)
Median time to response 8.3 months (range 1.9 - 15.9)
Disease control rate 40% (95% CI: 26 -55%)
PFS at 6 months 35% (95% CI: 21 - 49%); PFS at 12 months 30% (95% CI: 17 -44%)
Overall survival
●
●
12 months: 57% (95% CI:41 - 70%)
24 months: 35% (95% CI: 21 - 49%)
Improvements observed in performance status and reduction in corticosteroid use
One SAE was considered possibly related to ONC201 by investigator and unlikely related to ONC201 by
sponsor
O 2021 Chimerix, IncView entire presentation